Luckily, RB1 and CDK4 mutations seem to be mutually exclusive in osteosarcomas and thus CDK4/6 inhibition may be applied without fear of reverting mutations, although they could occur as a response to multimodal chemotherapy. The gene discussed is CDK4; the disease is osteosarcoma.